146 related articles for article (PubMed ID: 38153228)
1. Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia.
Tokatlı M; Ismayilov R; Erkin Çınar O; Haznedaroğlu İC
Turk J Haematol; 2024 Mar; 41(1):59-60. PubMed ID: 38153228
[No Abstract] [Full Text] [Related]
2. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
Mirault T; Rea D; Azarine A; Messas E
Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
[TBL] [Abstract][Full Text] [Related]
3. [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].
Gautier V; Mirault T; Azarine A; Alsac JM; Sapoval M; Réa D; Messas E
J Mal Vasc; 2015 Jul; 40(4):231-9. PubMed ID: 26139550
[TBL] [Abstract][Full Text] [Related]
4. Development of psoriasis in a patient with chronic myelogenous leukaemia during nilotinib treatment.
Nagai T; Karakawa M; Komine M; Muroi K; Ohtsuki M; Ozawa K
Eur J Haematol; 2013 Sep; 91(3):270-272. PubMed ID: 23734955
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia.
Sarlon-Bartoli G; Michel Q; Sarlon E; Carcopino-Tusoli M; Suchon P; Soler R; Bartoli MA; Brunet D; Morange P; Charbonnier A
J Med Vasc; 2021 Apr; 46(2):66-71. PubMed ID: 33752848
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
[No Abstract] [Full Text] [Related]
7. The link between interleukin-1β and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study.
Mori H; Sukegawa M; Fukatsu M; Sano T; Takahashi H; Harada K; Kimura S; Ohkawara H; Nakamura K; Mita M; Saito T; Hamazaki Y; Ohta M; Ikezoe T
Ann Hematol; 2020 Feb; 99(2):359-361. PubMed ID: 31872359
[No Abstract] [Full Text] [Related]
8. T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.
Hanley B; Nesr G; Yebra-Fernandez E; Brown L; Rabitsch A; Killeen N; Claudiani S; Milojkovic D; Kanfer E; Apperley J; Naresh KN
J Clin Pathol; 2019 Jul; 72(7):511-512. PubMed ID: 31004076
[No Abstract] [Full Text] [Related]
9. [Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
Rea D; Ame S; Charbonnier A; Coiteux V; Cony-Makhoul P; Escoffre-Barbe M; Etienne G; Gardembas M; Guerci-Bresler A; Legros L; Nicolini F; Tulliez M; Hermet E; Huguet F; Johnson-Ansah H; Lapusan S; Quittet P; Rousselot P; Mahon FX; Messas E
Bull Cancer; 2016 Feb; 103(2):180-9. PubMed ID: 26790711
[TBL] [Abstract][Full Text] [Related]
10. Symptomatic acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukaemia.
Mansour K; Ben Sayed N; Ouni B
Med Clin (Barc); 2024 Jan; 162(2):91-92. PubMed ID: 37838535
[No Abstract] [Full Text] [Related]
11. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
[TBL] [Abstract][Full Text] [Related]
12. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Khouri S; Kotliroff A; Lishner M; Amital H
Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
[No Abstract] [Full Text] [Related]
13. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
[TBL] [Abstract][Full Text] [Related]
15. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
[TBL] [Abstract][Full Text] [Related]
16. Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.
Kaune KM; Baumgart M; Gesk S; Mitteldorf C; Baesecke J; Glass B; Haase D; Siebert R; Ghadimi BM; Neumann C; Emmert S
Arch Dermatol; 2008 Mar; 144(3):361-4. PubMed ID: 18347292
[TBL] [Abstract][Full Text] [Related]
17. Multiple squamous cell carcinomas following introduction of nilotinib.
Peters P; Rabbolini D; Sinnya S; Khosrotehrani K; Wagner G
Clin Exp Dermatol; 2014 Oct; 39(7):791-4. PubMed ID: 25155911
[TBL] [Abstract][Full Text] [Related]
18. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Novitzky-Basso I; Craddock C
Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
[No Abstract] [Full Text] [Related]
19. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
[No Abstract] [Full Text] [Related]
20. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.
Lai GM; Yan SL; Chang CS; Tsai CY
World J Gastroenterol; 2013 Feb; 19(8):1318-21. PubMed ID: 23483799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]